See more : Sandston Corporation (SDON) Income Statement Analysis – Financial Results
Complete financial analysis of Ampio Pharmaceuticals, Inc. (AMPE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ampio Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Olympio Metals Limited (COPGF) Income Statement Analysis – Financial Results
- The Star Entertainment Group Limited (SGR.AX) Income Statement Analysis – Financial Results
- The Necessity Retail REIT, Inc. (RTLPP) Income Statement Analysis – Financial Results
- Bank Millennium S.A. (MIL.WA) Income Statement Analysis – Financial Results
- Bedding World Co., Ltd. (2938.TWO) Income Statement Analysis – Financial Results
Ampio Pharmaceuticals, Inc. (AMPE)
About Ampio Pharmaceuticals, Inc.
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.16M | 76.79K | 50.00K | 50.00K | 18.75K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 250.00K | 2.08M | 1.09M | 1.18M | 1.27M | 523.00K | 568.00K | 950.00K | 369.31K | 2.24M | 1.74M | 1.45M | 0.00 | 0.00 | 0.00 | 950.00 | 0.00 | 0.00 |
| Gross Profit | -250.00K | -2.08M | -1.09M | -1.18M | -1.27M | -523.00K | -568.00K | -950.00K | 793.15K | -2.16M | -1.69M | -1.40M | 18.75K | 0.00 | 0.00 | -950.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 68.23% | -2,818.46% | -3,376.00% | -2,798.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.44M | 8.92M | 11.90M | 9.17M | 12.62M | 6.83M | 10.42M | 10.55M | 18.96M | 26.92M | 18.29M | 7.49M | 6.65M | 1.97M | 1.07M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 7.08M | 11.47M | 8.67M | 6.65M | 5.90M | 4.36M | 5.14M | 6.54M | 15.14M | 12.23M | 5.79M | 4.38M | 4.50M | 4.73M | 21.87K | 28.28K | 27.80K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.08M | 11.47M | 8.67M | 6.65M | 5.90M | 4.36M | 5.14M | 6.54M | 15.14M | 12.23M | 5.79M | 4.38M | 4.50M | 4.73M | 21.87K | 28.28K | 27.80K | 0.00 |
| Other Expenses | 0.00 | 1.94M | 0.00 | 12.00K | 56.00K | 0.00 | 323.55K | 143.80K | 0.00 | 0.00 | 0.00 | 0.00 | 34.01K | 0.00 | 0.00 | 950.00 | 1.20K | 0.00 |
| Operating Expenses | 9.27M | 20.38M | 20.57M | 15.83M | 18.58M | 11.18M | 15.56M | 17.08M | 34.10M | 39.15M | 24.07M | 11.87M | 11.15M | 6.70M | 21.87K | 29.23K | 29.00K | 1.00K |
| Cost & Expenses | 9.52M | 20.38M | 20.57M | 15.83M | 18.58M | 11.18M | 15.56M | 17.08M | 34.46M | 39.15M | 24.07M | 11.87M | 11.15M | 6.70M | 21.87K | 29.23K | 29.00K | 1.00K |
| Interest Income | 348.00K | 220.00K | 4.00K | 12.00K | 77.00K | 5.00K | 3.09K | 23.48K | 59.85K | 22.26K | 12.29K | 21.94K | 6.68K | 815.00 | 1.09K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 77.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.36K | 19.55K | 4.18K | 2.65K | 0.00 | 0.00 |
| Depreciation & Amortization | 127.00K | 2.08M | 1.09M | 1.18M | 1.27M | 1.28M | 1.21M | 1.21M | 1.14M | 439.10K | 137.68K | 62.40K | 42.55K | 815.00 | 0.00 | 0.00 | 2.19K | 0.00 |
| EBITDA | 0.00 | -18.30M | 0.00 | 0.00 | -17.30M | 35.26M | -14.46M | -14.81M | -23.34M | 0.00 | -23.89M | -11.76M | -11.08M | -8.01M | -21.87K | -29.23K | -26.81K | -1.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,760.35% | -50,310.73% | -47,747.81% | -23,472.97% | -59,119.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.52M | -24.21M | -25.16M | -15.22M | -23.45M | -11.18M | -15.56M | -17.08M | -33.30M | -39.07M | -24.02M | -11.82M | -11.13M | -6.70M | -21.87K | -29.23K | -29.00K | -1.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,864.79% | -50,882.57% | -48,047.74% | -23,641.65% | -59,382.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 886.00K | 4.05M | 3.50M | -60.00K | 4.95M | 45.17M | -36.22M | -2.08M | -412.07K | -7.60M | -504.16K | 227.29K | -7.14M | -1.35M | -4.18K | -2.65K | -2.19K | 0.00 |
| Income Before Tax | -8.63M | -16.34M | -17.08M | -15.89M | -13.63M | 33.99M | -51.89M | -19.16M | -33.71M | -39.05M | -24.53M | -11.59M | -18.28M | -8.05M | -26.05K | -31.88K | -31.20K | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,900.24% | -50,853.58% | -49,056.85% | -23,186.23% | -97,475.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -7.87M | -4.59M | 604.00K | -4.95M | 45.17M | 36.33M | 1.04M | -1.29M | -923.52K | -519.87K | -68.00 | 82.50K | 18.73K | 0.00 | 0.00 | 800.00 | 1.00K |
| Net Income | -8.63M | -8.47M | -12.49M | -16.50M | -8.68M | 33.99M | -51.89M | -19.16M | -32.01M | -38.13M | -24.01M | -11.59M | -18.36M | -8.05M | -26.05K | -31.88K | -32.00K | -1.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,753.66% | -49,650.87% | -48,017.12% | -23,186.09% | -97,915.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -10.67 | -11.24 | -18.79 | -28.63 | -18.32 | 92.10 | -239.13 | -107.06 | -184.70 | -227.72 | -188.09 | -102.34 | -211.73 | -137.54 | -0.53 | -0.51 | -0.52 | -0.02 |
| EPS Diluted | -10.66 | -11.24 | -18.59 | -27.71 | -18.32 | 91.90 | -238.41 | -106.91 | -184.70 | -227.72 | -188.09 | -102.34 | -211.73 | -137.54 | -0.53 | -0.51 | -0.52 | -0.02 |
| Weighted Avg Shares Out | 809.00K | 753.62K | 664.33K | 576.16K | 474.03K | 369.00K | 217.00K | 179.00K | 173.31K | 167.42K | 127.65K | 113.28K | 86.71K | 58.56K | 49.31K | 61.98K | 61.98K | 61.98K |
| Weighted Avg Shares Out (Dil) | 810.11K | 753.62K | 671.49K | 595.41K | 474.03K | 369.81K | 217.66K | 179.24K | 173.31K | 167.42K | 127.65K | 113.28K | 86.71K | 58.56K | 49.31K | 61.98K | 61.98K | 61.98K |
Which Strategies Are You Using With Penny Stocks in September?
Are you using these strategies for trading penny stocks right now? The post Which Strategies Are You Using With Penny Stocks in September?
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ampio Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – AMPE
NEW YORK–(BUSINESS WIRE)–WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) between December 29, 2020 and August 3, 2022, both dates inclusive (the “Class Period”), of the...
Why These 3 Penny Stocks Are Climbing in Late April
Are these three penny stocks on your watchlist right now? The post Why These 3 Penny Stocks Are Climbing in Late April appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Ampio Pharma Shares Fall As FDA Rejects Proposed Change In Knee Osteoarthritis Trial
Ampio Pharmaceuticals Inc (NYSE: AMPE) received written responses from the FDA pursuant to a Type C meeting request regarding the AP-013 Phase 3 trial results. In March, Ampio announced data from the modified Intent-To-Treat (mITT) population (n=618) in the AP-013 study...
New Strong Sell Stocks for April 7th
AMPE, ANIK, and FAT have been added to the Zacks Rank #5 (Strong Sell) List on April 7, 2022.
New Strong Sell Stocks for April 1st
AKYA, AMPE, and BITF have been added to the Zacks Rank #5 (Strong Sell) List on April 1, 2022.
Ampio Pharmaceuticals, Inc. (AMPE) CEO Michael Martino on Q4 2021 Results - Earnings Call Transcript
Ampio Pharmaceuticals, Inc. (AMPE) CEO Michael Martino on Q4 2021 Results - Earnings Call Transcript
Why Ampio Pharmaceuticals Stock Is Rising Today
Ampio Pharmaceuticals Inc (AMEX:AMPE) shares are trading significantly higher Thursday following bullish analyst coverage. Alliance Global Partners analyst James Molloy initiated coverage on Ampio Pharmaceuticals with a Buy rating and announced a $4.50 price target, which is well.
Ampio (AMPE) Upgraded to Buy: Here's What You Should Know
Ampio (AMPE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Down 25.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Ampio (AMPE)
The heavy selling pressure might have exhausted for Ampio (AMPE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is...
Source: https://incomestatements.info
Category: Stock Reports